

United States Patent and Trademark Office  
- Sales Receipt -

01/11/2006 DWILLIA4 00000002 071392 10070084

01 FC:1252 450.00 DA

DEC. 22. 2005 3:30PM GLAXO WELLCOME

NO. 8830 P. 2

Serial No. 10/070,084  
Docket No. PU3517USw  
Reply to Office Action of December 16, 2004

RECEIVED  
Docket No. PU3517USw CENTRAL FAX CENTER

DEC 22 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: C. W. Andrews et al.

SERIAL NO. 10/070,084

ART UNIT: 1624

FILED: March 7, 2002

EXAMINER: Deepak R. Rao

FOR: BENZOPHENONES AS INHIBITORS OF REVERSE TRANSCRIPTASE

Commissioner of Patents  
P.O. Box 1450  
Alexandria VA 22313-1459

Response under 37 C.F.R. § 1.111

Sir:

This Amendment is in response to the Office Action dated July 26, 2005 for which the period for response expired on October 26, 2005. Applicants hereby request a two-month extension of time to extend the response period up to and including December 26, 2005. Please charge Deposit Account No. 07-1392 in the amount of \$450.00. Please amend the application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 29 of this paper.

BEST AVAILABLE COPY

1 of 31

Serial No. 10/070,084  
Docket No. PU3517USw  
Reply to Office Action of December 16, 2004

5. One of ordinary skill in the art would easily understand the difference between a monovalent alkyl and a bivalent alkyl based upon the formula as written. As stated above, one of ordinary skill in the art would understand that, as shown in the examples, if R<sup>11</sup> is an alkyl, then the R<sup>11</sup> connecting, or between -O and -OR<sup>11</sup> is a bivalent group. As previously indicated, an illustration of the term "-OR<sup>11</sup>OR<sup>11</sup>" is provided by Examples 250, 251, and 252 on pages 359 - 361.

6. Claim 18 has been amended to correct a typographical error. Therefore, this rejection is moot.

7. Claims 26 and 43-47 have been amended to remove "particularly". According, this rejection is moot.

8. Claim 40 has been amended to delete the term "R<sup>3</sup>". Accordingly, this rejection is moot.

9. Claim 48 and 49 have been amended, therefore, this rejection is moot.

Examiner's points 1 through 9 having been addressed, Applicants respectfully request withdrawal of the rejection of claims 2 - 7, 9 - 14, 18 - 20, 26, 28, 29, 34 - 36, 40, 43-51, 54 and 56 - 62 under 35 U.S.C. § 112, second paragraph.

In view of the amendments and foregoing discussion, it is respectfully submitted that the present application is in condition for allowance. An early consideration and notice of allowance are earnestly solicited.

The Commissioner is hereby authorized to charge any fees required or credit any overpayment to Deposit Account No. 07-1392.

Respectfully submitted,

Kimberly H. Parker  
Attorney for Applicant  
Reg. No. 47,843

Date: Dec. 22, 2005

Customer No. 23347  
GlaxoSmithKline  
Corporate Intellectual Property Department  
Five Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709  
Tel: (919) 483-8406  
Fax: (919) 483-7988

BEST AVAILABLE COPY